Dual CD33/CLL1 targeting CAR-T therapy - Sichuan Kelun-Biotech Biopharmaceutical
Alternative Names: CD33-CLL1 CAR; Chimeric-Antigen-Receptor-immunotherapy; Dual CD33-CLL1 CAR-T Therapy; Dual-CD33/CLL1-targeting-CAR-T therapyLatest Information Update: 09 Sep 2021
At a glance
- Originator Sichuan Kelun-Biotech Biopharmaceutical
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 30 Aug 2021 Preclinical trials in Acute myeloid leukaemia in China (Parenteral) (Sichuan Kelun-Biotech Biopharmaceutical pipeline, August 2021)
- 23 Aug 2021 Xinqiao Hospital of Chongqing and Sichuan Kelun-Biotech Biopharmaceutical plans a phase I trial for Acute myeloid leukemia (Second-line therapy or greater) in China (Parenteral) (NCT05016063)